Efficacy of Half of Europe’s New Cancer Drugs ‘Uncertain’
It’s a bitter pill to swallow. A new study reveals that the European Medicines Agency approved 39 new cancer drugs during a recent five-year period without any evidence that they worked. The drug regulator green-lighted 68 cancer drugs between 2009 and 2013 — only about half of which actually boosted patients’ quality of life or survival rate. The EMA “welcomes further debate” on the issue, but it’ll take more than just talk to fix what researchers say is a “broken” approval process in Europe’s regulatory system.